CA2168067A1 - Method for treating smoking-related bone loss - Google Patents
Method for treating smoking-related bone lossInfo
- Publication number
- CA2168067A1 CA2168067A1 CA002168067A CA2168067A CA2168067A1 CA 2168067 A1 CA2168067 A1 CA 2168067A1 CA 002168067 A CA002168067 A CA 002168067A CA 2168067 A CA2168067 A CA 2168067A CA 2168067 A1 CA2168067 A1 CA 2168067A1
- Authority
- CA
- Canada
- Prior art keywords
- piperidino
- alkyl
- bone loss
- pharmaceutically
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
A method for treating smoking-related bone loss which comprises administering to a human in need thereof a pharmaceutically-effective amount of a compound having the formula (I) wherein R1 and R3 are independently hydrogen, C1-C4 alkyl, -CO-(C1-C6 alkyl), or -CH2Ar, -CO-Ar, wherein Ar is phenyl or substituted phenyl;
R2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically-acceptable salt thereof.
R2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically-acceptable salt thereof.
Description
` - 2168067 Method For Treating Smoking-Related Bone Loss This invention relates to the discovery that a group of 2-aryl-3-aroylbenzo[b]thiophenes is useful in the treatment of smoking-related bone loss.
The mechanism of bone loss is not well understood, but in practical effect, the disorder arises from an imbalance in the formation of new healthy bone and the resorption of old bone, skewed toward a net loss of bone tissue. This bone loss includes a decrease in both mineral content and protein matrix components of the bone, and leads to an increased fracture rate of, predo~'n~ntly, femoral bones and bones in the forearm and vertebrae. These fractures, in turn, lead to an increase in general morbidity, a marked loss of stature and mobility, and, in many cases, an increase in mortality resulting from complications.
Unchecked, bone loss can lead to osteoporosis, a major debilitating disease whose prominent feature is the loss of bone mass (decreased density and increased porosity) without a reduction in bone volume, producing porosity and fragility.
Recent studies have suggested that smoking is a risk factor for bone fractures, especially of vertebral, forearm, and hip fractures. In one study, bone density of -women who smoked, or who smoked more heavily, was significantly lower than that of their twin sisters. See Hopper and Seeman, N. Engl. J. Med., 330(6), 387-392 (1994).
A decrease in bone density means an increased risk of osteoporotic fractures. In a second study, bone loss was accelerated in middle-aged men who were smokers. See Slemenda et al., Ann. Intern. Med., 117, 286-291 (1992).
These studies provide compelling evidence of an association between smoking and reduced bone density in both men and women.
Estrogen, either alone or combined with progestin, is currently recommended for preventing bone loss in postmenopausal women. Although estrogens have beneficial effects on bone, long-term estrogen therapy has been implicated in a variety of disorders, including an increased risk of uterine and breast cancer. Furthermore, the protective effects of estrogen therapy are eliminated for women smokers. See Kiel et al ., Ann. Intern. Med., 116(9), 716-721 (1992). This lack of protection is due to smoking-related increases in the sex-hormone binding globulin and hepatic metabolism of estrogens. See Slemenda, N. Engl. J.
Med., 330(6), 430-431 (1994) and Jensen et al., N. Engl. J.
Med., 313(6), 973-975 (1985). There currently are no treatments for smoking-related bone loss, therefore, there exists a need for treatment of bone loss in both men and women who smoke.
The present invention concerns the discovery that a select group of 2-aryl-3-aroylbenzo[b]thiophenes (benzo[b]-thiophenes), the compounds of formula I, are useful for treating smoking-related bone loss. The therapeutic pharmaceutical compositions and treatments provided by this invention are practiced by administering to a human a pharmaceutically-effective amount of a compound of formula I
or a pharmaceutically-acceptable salt thereof. According to the present invention, there is provided a method for treating smoking-related bone loss, thus serving as an effective and acceptable treatment for smoking-related osteoporosis.
The 2-aryl-3-aroylbenzo[b]thiophene compounds that are used in the methods of this invention were first developed by Jones and Suarez as anti-fertility agents. See U.S. Patent No. 4,133,814 (issued January 9, 1979). These compounds are generally useful in suppressing the growth of m~mm~ry tumors.
~ 2;16~067 Jones later found that a group of compounds are useful for antiestrogen and antiandrogen therapy, especially in the treatment of m~mm~ry and prostatic tumors. See U. S .
Patent 4,418,068 (issued November 29, 1983). One of these compounds, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidino-ethoxy)benzoyl]benzo[b]thiophene was clinically studied for the treatment of breast cancer. This compound is called raloxifene, formerly keoxifene.
This invention provides methods for treating smoking-related bone loss, which comprises administering to a human in need thereof an effective amount of a compound of the formula ,~ OCH2CH2--R2 ~
,_ = oR3 (I) wherein Rl and R3 are independently hydrogen, Cl-C4 alkyl, -CO-(Cl-C6 alkyl), -CH2Ar, or -CO-Ar, wherein Ar is phenyl or substituted phenyl;
R2 is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; or a pharmaceutically-acceptable salt thereof. The present invention also provides the use of the formula I compounds, or pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of smo~ing-related bone loss.
In the above formula, the term "Cl-C6 alkyl'~
represents a straight, cyclic, or branched alkyl chain having from one to six carbon atoms. Typical Cl-C6 alkyl groups ~ ~ 2163067 include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, n-hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. The term "C1-C4 alkyl" represents a straight or branched alkyl chain having one to four carbon atoms.
Typical C1-C4 alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, secbutyl, isobutyl, and t-butyl.
The term "Ar" represents groups such as phenyl and substituted phenyl. The term ~'substituted phenyl", as used herein, represents a phenyl group substituted with one or more moieties chosen from the group consisting of halogen, hydroxy, cyano, nitro, C1-C4 alkyl, C1-C4 alkoxy, acetyl, - formyl, trichloromethyl, or trifluoromethyl. Examples of a substituted phenyl group include 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 3-chlorophenyl, 3-bromophenyl, 4-bromophenyl, 3,4-dibromo-phenyl, 3-chloro-4-fluorophenyl, 2-fluorophenyl, 4-hydroxyphenyl, 3-hydroxyphenyl, 2,4-dihydroxyphenyl, 3-nitrophenyl, 4-nitrophenyl, 4-cyanophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-propylphenyl, 4-n-butylphenyl, 4-t-butylphenyl, 3-fluoro-2-methylphenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,6-dimethylphenyl, 2-fluoro-5-methylphenyl, 2,4,6-trifluorophenyl, 2-trifluoromethylphenyl, 2-chloro-5-trifluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3,5-dimethoxyphenyl, 4-hydroxy-3-methylphenyl, 3,5-dimethyl-4-hydroxyphenyl, 2-methyl-4-nitrophenyl, 4-methoxy-2-nitrophenyl, 2,4-dinitrophenyl, and the like. The term "C1-C4 alkoxy~ represents groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, and the like. The term '~halogen~ represents fluoro, chloro, bromo, and iodo.
The term ~smoking-related bone loss~' refers to decreases in bone mineral content, decreases in bone density, increases in bone porosity, and/or decreases in the protein matrix components of bone, which are attributable to smoking.
- ~ ~168067 The term "pharmaceutically-effective amount" is used herein to represent an amount of the formula I compound that is capable of treating smoking-related bone loss. The term "treating" includes inhibiting, preventing, or restraining further bone loss and slowing, stopping progression, or severity of a resultant symptom. The particular dose of the formula I compound will of course be determined by the particular circumstances surrounding the case, including the compound administered, the route of administration, the particular condition treated, and similar considerations.
While all the formula I compounds are useful for treating smoking-related bone loss, certain compounds are preferred. Preferably, Rl and R3 are independently hydrogen, Cl-C4 alkyl, -CO-(Cl-C6 alkyl), or benzyl, and R2 is piperidino or pyrrolidino. Representative compounds from this preferred group include 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-pyrrolidinoethoxy)benzoyl]benzo[b]thiophene, 6-methoxy-2-(4-methoxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo-[b]thiophene, 6-acetoxy-2-(4-acetoxyphenyl)-3-[4-(2-pyrrolidinoethoxy)benzoyl]benzo[b]thiophene, and 6-benzyloxy-2-(4-benzyloxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]thiophene.
More preferably, Rl and R3 are independently hydrogen or Cl-C4 alkyl, and R2 is piperidino or pyrrolidino.
Representative compounds from this more preferred group include 6-hydroxy-2-(4-hydrophenyl)-3-[4-(2-pyrrolidino-ethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-2-(4-hydroxy-phenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene, 6-methoxy-2-(4-methoxyphenyl)-3-[4-(2-pyrrolidinoethoxy)-benzoyl]benzo[b]thiophene, and 6-methoxy-2-(4-methoxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene. Most preferably, Rl and R3 are hydrogen and R2 is piperidino. This most preferred compound is 6-hyaroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene.
The formula I compounds used in the methods of the present invention can be made according to established procedures, such as those described in U.S. Patent Nos.
The mechanism of bone loss is not well understood, but in practical effect, the disorder arises from an imbalance in the formation of new healthy bone and the resorption of old bone, skewed toward a net loss of bone tissue. This bone loss includes a decrease in both mineral content and protein matrix components of the bone, and leads to an increased fracture rate of, predo~'n~ntly, femoral bones and bones in the forearm and vertebrae. These fractures, in turn, lead to an increase in general morbidity, a marked loss of stature and mobility, and, in many cases, an increase in mortality resulting from complications.
Unchecked, bone loss can lead to osteoporosis, a major debilitating disease whose prominent feature is the loss of bone mass (decreased density and increased porosity) without a reduction in bone volume, producing porosity and fragility.
Recent studies have suggested that smoking is a risk factor for bone fractures, especially of vertebral, forearm, and hip fractures. In one study, bone density of -women who smoked, or who smoked more heavily, was significantly lower than that of their twin sisters. See Hopper and Seeman, N. Engl. J. Med., 330(6), 387-392 (1994).
A decrease in bone density means an increased risk of osteoporotic fractures. In a second study, bone loss was accelerated in middle-aged men who were smokers. See Slemenda et al., Ann. Intern. Med., 117, 286-291 (1992).
These studies provide compelling evidence of an association between smoking and reduced bone density in both men and women.
Estrogen, either alone or combined with progestin, is currently recommended for preventing bone loss in postmenopausal women. Although estrogens have beneficial effects on bone, long-term estrogen therapy has been implicated in a variety of disorders, including an increased risk of uterine and breast cancer. Furthermore, the protective effects of estrogen therapy are eliminated for women smokers. See Kiel et al ., Ann. Intern. Med., 116(9), 716-721 (1992). This lack of protection is due to smoking-related increases in the sex-hormone binding globulin and hepatic metabolism of estrogens. See Slemenda, N. Engl. J.
Med., 330(6), 430-431 (1994) and Jensen et al., N. Engl. J.
Med., 313(6), 973-975 (1985). There currently are no treatments for smoking-related bone loss, therefore, there exists a need for treatment of bone loss in both men and women who smoke.
The present invention concerns the discovery that a select group of 2-aryl-3-aroylbenzo[b]thiophenes (benzo[b]-thiophenes), the compounds of formula I, are useful for treating smoking-related bone loss. The therapeutic pharmaceutical compositions and treatments provided by this invention are practiced by administering to a human a pharmaceutically-effective amount of a compound of formula I
or a pharmaceutically-acceptable salt thereof. According to the present invention, there is provided a method for treating smoking-related bone loss, thus serving as an effective and acceptable treatment for smoking-related osteoporosis.
The 2-aryl-3-aroylbenzo[b]thiophene compounds that are used in the methods of this invention were first developed by Jones and Suarez as anti-fertility agents. See U.S. Patent No. 4,133,814 (issued January 9, 1979). These compounds are generally useful in suppressing the growth of m~mm~ry tumors.
~ 2;16~067 Jones later found that a group of compounds are useful for antiestrogen and antiandrogen therapy, especially in the treatment of m~mm~ry and prostatic tumors. See U. S .
Patent 4,418,068 (issued November 29, 1983). One of these compounds, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidino-ethoxy)benzoyl]benzo[b]thiophene was clinically studied for the treatment of breast cancer. This compound is called raloxifene, formerly keoxifene.
This invention provides methods for treating smoking-related bone loss, which comprises administering to a human in need thereof an effective amount of a compound of the formula ,~ OCH2CH2--R2 ~
,_ = oR3 (I) wherein Rl and R3 are independently hydrogen, Cl-C4 alkyl, -CO-(Cl-C6 alkyl), -CH2Ar, or -CO-Ar, wherein Ar is phenyl or substituted phenyl;
R2 is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; or a pharmaceutically-acceptable salt thereof. The present invention also provides the use of the formula I compounds, or pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of smo~ing-related bone loss.
In the above formula, the term "Cl-C6 alkyl'~
represents a straight, cyclic, or branched alkyl chain having from one to six carbon atoms. Typical Cl-C6 alkyl groups ~ ~ 2163067 include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, n-hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. The term "C1-C4 alkyl" represents a straight or branched alkyl chain having one to four carbon atoms.
Typical C1-C4 alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, secbutyl, isobutyl, and t-butyl.
The term "Ar" represents groups such as phenyl and substituted phenyl. The term ~'substituted phenyl", as used herein, represents a phenyl group substituted with one or more moieties chosen from the group consisting of halogen, hydroxy, cyano, nitro, C1-C4 alkyl, C1-C4 alkoxy, acetyl, - formyl, trichloromethyl, or trifluoromethyl. Examples of a substituted phenyl group include 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 3-chlorophenyl, 3-bromophenyl, 4-bromophenyl, 3,4-dibromo-phenyl, 3-chloro-4-fluorophenyl, 2-fluorophenyl, 4-hydroxyphenyl, 3-hydroxyphenyl, 2,4-dihydroxyphenyl, 3-nitrophenyl, 4-nitrophenyl, 4-cyanophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-propylphenyl, 4-n-butylphenyl, 4-t-butylphenyl, 3-fluoro-2-methylphenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,6-dimethylphenyl, 2-fluoro-5-methylphenyl, 2,4,6-trifluorophenyl, 2-trifluoromethylphenyl, 2-chloro-5-trifluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3,5-dimethoxyphenyl, 4-hydroxy-3-methylphenyl, 3,5-dimethyl-4-hydroxyphenyl, 2-methyl-4-nitrophenyl, 4-methoxy-2-nitrophenyl, 2,4-dinitrophenyl, and the like. The term "C1-C4 alkoxy~ represents groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, and the like. The term '~halogen~ represents fluoro, chloro, bromo, and iodo.
The term ~smoking-related bone loss~' refers to decreases in bone mineral content, decreases in bone density, increases in bone porosity, and/or decreases in the protein matrix components of bone, which are attributable to smoking.
- ~ ~168067 The term "pharmaceutically-effective amount" is used herein to represent an amount of the formula I compound that is capable of treating smoking-related bone loss. The term "treating" includes inhibiting, preventing, or restraining further bone loss and slowing, stopping progression, or severity of a resultant symptom. The particular dose of the formula I compound will of course be determined by the particular circumstances surrounding the case, including the compound administered, the route of administration, the particular condition treated, and similar considerations.
While all the formula I compounds are useful for treating smoking-related bone loss, certain compounds are preferred. Preferably, Rl and R3 are independently hydrogen, Cl-C4 alkyl, -CO-(Cl-C6 alkyl), or benzyl, and R2 is piperidino or pyrrolidino. Representative compounds from this preferred group include 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-pyrrolidinoethoxy)benzoyl]benzo[b]thiophene, 6-methoxy-2-(4-methoxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo-[b]thiophene, 6-acetoxy-2-(4-acetoxyphenyl)-3-[4-(2-pyrrolidinoethoxy)benzoyl]benzo[b]thiophene, and 6-benzyloxy-2-(4-benzyloxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]thiophene.
More preferably, Rl and R3 are independently hydrogen or Cl-C4 alkyl, and R2 is piperidino or pyrrolidino.
Representative compounds from this more preferred group include 6-hydroxy-2-(4-hydrophenyl)-3-[4-(2-pyrrolidino-ethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-2-(4-hydroxy-phenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene, 6-methoxy-2-(4-methoxyphenyl)-3-[4-(2-pyrrolidinoethoxy)-benzoyl]benzo[b]thiophene, and 6-methoxy-2-(4-methoxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene. Most preferably, Rl and R3 are hydrogen and R2 is piperidino. This most preferred compound is 6-hyaroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene.
The formula I compounds used in the methods of the present invention can be made according to established procedures, such as those described in U.S. Patent Nos.
4,133,814, 4,418,068, and 4,380,635, all of which are incorporated by reference herein. In general, the process starts with 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene.
This starting compound is protected, acylated at C-3 with a 4-(2-aminoethoxy)benzoyl group, and optionally deprotected to form the formula I compounds. Examples of the preparation of such compounds are provided in the U.S. Patents discussed above.
The compounds used in the methods of this invention form pharmaceutically-acceptable acid and, wherein Rl and/or R3 is hydrogen, base addition salts with a wide variety of organic and inorganic acids and bases, including the physiologically-acceptable salts which are often used in pharmaceutical chemistry. Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydriodic, nitric, sulfuric, phosphoric, hypophosphoric, and the like.
Salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used.
Such pharmaceutically-acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, and ~-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,6-dioate, caprate, caprylate, chloride, cinn~m~te~ cltrate, formate, fumarate, glycolate, heptanoate, decanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, terephthalate, phosphate, monohydro-genphosphate, dihydrogenphosphate, metaphosphate,pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzenesulfonate, p-bromophenylsulfonate, chlorobenzene-sulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methanesulfonate, naphthalene-l-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartrate, and the like. The most preferred salt is the hydrochloride salt.
The pharmaceutically-acceptable acid addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid. The reactants are generally combined in an organic solvent such as methanol, diethyl ether, or benzene. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration, or the solvent can be stripped off by conventional means.
Bases commonly used for formation of salts include ammonium hydroxide and alkali and alkaline earth metal hydroxides, carbonates, as well as aliphatic primary, secondary, and tertiary amines, and aliphatic diamines.
Bases especially useful in the preparation of addition salts include ammonium hydroxide, potassium carbonate, methylamine, diethylamine, ethylenediamine, and cyclohexylamine. These salts are generally prepared by reacting a formula I
compound, wherein Rl and/or R3 are hydrogen, with one of the above bases in an organic solvent, such as methanol, diethyl ether, or benzene. The salts are isolated as described in the preceding paragraph.
These pharmaceutically-acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.
The formula I compounds are preferably formulated prior to administration such as in a pharmaceutical formulation comprising a compound of formula I and a pharmaceutically-acceptable carrier, diluent, or excipient.
These pharmaceutical formulations are prepared by known procedures using well-known and readily available ingredients. In making these compositions, the active ingredient will usually be mixed with a carrier, diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, excipient,or medium for the active ingredient. The compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments containing, for example up to 10% by weight of active compound, soft and hard gelatin capsules, dermal patches, suppositories, sterile injectible solutions, and sterile packaged powders.
Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, micro-crystalline cellulose, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, cellulose or derivatives thereof, water syrup, methyl cellulose, methyl and propyl hydroxybenzoates, talc, magnesium sterate and mineral oil. The formulations can additionally include lubricating agents, wetting agents (e.g. surfactant), emulsifying and suspending agents, disintegrating agents, preserving agents, sweetening agents, or flavoring agents. Compositions of the inventions may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
The particular dosage of a compound of formula I
required to treat smoking-related bone loss or its symptoms, according to this invention, will depend upon the severity of the condition, the route of a & inistration, and related factors that will be decided by the attending physician.
Generally, effective daily doses will be from about 0.1 to about 1000 mg/day, and more typically from about 50 to about 200 mg/day. Such dosages will be a & inistered to a subject ~ 216~067 in need thereof from once to about three times each day, or more often as needed to effectively treat the condition or symptom.
It is usually preferred to administer a compound of formula I in the form of an acid addition salt, as is customary in the administration of pharmaceuticals bearing a basic group, such as the piperidino group. For such purposes the following oral dosage forms are available.
Formulations In the formulations which follow, ~Active ingredient" means a compound of formula I.
Formulation 1: Gelatin Capsules Hard gelatin capsules are prepared using the following:
Ingredient Quantity (mg/capsule) Active ingredient0.1 - 1000 Starch, NF O - 650 Starch flowable powder 0 - 650 Silicone fluid 350 centistokes 0 - 15 The ingredients are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules.
Examples of specific capsule formulations of raloxifene that have been made include those shown below:
Formulation 2: Raloxifene capsule Inqredient Quantity (mq/capsule) Raloxifene Starch, NF 112 Starch flowable powder 225.3 Silicone fluid 350 centistokes 1.7 i~ ~168067 Formulation 3: Raloxifene capsule Ingredient Quantity (mg/capsule) Raloxifene 5 Starch, NF 108 Starch flowable powder 225.3 Silicone fluid 350 centistokes 1.7 Formulation 4: Raloxifene capsule Ingredient Quantity (mq/capsule) Raloxifene 10 Starch, NF 103 Starch flowable powder 225.3 Silicone fluid 350 centistokes 1.7 Formulation 5: Raloxifene capsule Ingredient Quantity (mg/capsule) Raloxifene 50 Starch, NF 150 Starch flowable powder 397 Silicone fluid 350 centistokes 3.0 The specific formulations above may be changed in compliance with the reasonable variations provided.
A tablet formulation is prepared using the ingredients below:
Formulation 6: Tablets Ingredient Quantity (mg/tablet) Active ingredient 0.1 - 1000 Cellulose, microcrystalline0 - 650 Silicon dioxide, fumed 0 - 650 Stearate acid 0 - 15 The components are blended and compressed to form tablets.
Alternatively, tablets each containing 0.1 - 1000 mg of Active ingredient are made up as follows:
Formulation 7: Tablets Ingredient Quantity (mg/tablet) Active ingredient 0.1 - 1000 Starch 45 Cellulose, microcrystalline35 Polyvinylpyrrolidone 4 (as 10% solution in water) Sodium carboxymethyl cellulose 4.5 Magnesium stearate 0.5 Talc The Active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly.
The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50-60 C
and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 U.S. sieve, are then added 21630~ ~
to the granules which, after mixing, are compressed on a tablet machine to yield tablets.
Suspensions each containing 0.1 - 1000 mg of Active ingredient per 5 mL dose are made as follows:
Formul a t i on 8: Suspensi ons Ingredient Quantity (mg/5 ml) Active ingredient0.1 - 1000 mg Sodium carboxymethyl cellulose 50 mg Syrup 1.25 mg Benzoic acid solution 0.10 mL
Flavor q.v.
Color q.v.
Purified water to 5 mL
The Active ingredient is passed through a No. 45 mesh U.S.
sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.
- 216 ~ 0 6 i -Illustrative compounds that can be used in the methods of the present invention are shown in Table 1.
Table Compound No. Rl and R3 R2 Form 1 -C(O) ~ F piperidino base 2 -C(O) ~ F piperidino HCl 3 -C(O) ~ piperidino base 4 -C(O) ~ piperidino HCl -C(O)CH2CH2CH3 piperidino base 6 -C(O)CH2CH2CH3 piperidino HCl 7 -C(O)C(CH3)3 piperidino base 8 -C(O)C(CH3)3 piperidino HCl g -C(O)CH2C(CH3)3 piperidino base 10 -c(o)cH2c(cH3)3 piperidino HCl 11 -C(O) ~ CH3 piperidino HCl 12 -C(O) ~ piperidino base 13 H piperidino base 14 H piperidino HCl H pyrrolodino base 16 H pyrrolodino HCl 17 Hhexamethyleneimino HCl 18 CH3piperidino HCl The utility of the compounds of formula I is illustrated by the positive impact they have in at least one of the assays described below.
~ ` 2168067 Example A model of post-menopausal osteoporosis was used in which effects of different treatments upon femur density were determined. Seventy-five day old female Sprague Dawley rats (weight range of 225 g to 275 g) were obtained from Charles River Laboratories (Portage, MI). They were housed in groups of 3 and had ad libitum access to food (calcium content approximately 1%) and water. Room temperature was maintained at 22.2 + 1.7 C with a minimum relative humidity of 40%.
The photoperiod in the room was 12 hours light and 12 hours dark.
One week after arrival, the rats underwent bilateral ovariectomy under anesthesia [44 mg/kg Ketamine and 5 mg/kg Xylazine (Butler, Indianapolis, IN) administered intramuscularly]. Treatment with vehicle, estrogen, or a compound of formula I was initiated on the day of surgery following recovery from anesthesia. Oral dosage was by gavage in 0.5 mL of 1% carboxymethylcellulose (CMC). Body weight was determined at the time of surgery and weekly thereafter and the dosage was adjusted with changes in body weight. Vehicle or estrogen treated ovariectomized (ovex) rats and non-ovariectomized (intact) rats were evaluated in parallel with each experimental group to serve as negative and positive controls.
The rats were treated daily for 35 days (6 rats per treatment group) and sacrificed by decapitation on the 36th day. The 35 day time period was sufficient to allow maximal reduction in bone density, measured as described herein. The right femurs were excised and scanned at the distal metaphysis 1 mm from the patellar groove with single photon absorptiometry. Results of the densitometer measurements represent a calculation of bone density as a function of the bone mineral content and bone width.
The results of control treatments from five separate experiments are accumulated in Table 2. In summary, ovariectomy of the rats caused a reduction in femur density of about 25% as compared to intact vehicle treated controls.
Estrogen, administered in the orally active form of ethynyl estradiol (EE2), prevented this loss of bone in a dose dependent manner. Results are reported as the mean of measurements from thirty rats + the standard error of the mean.
In these studies, raloxifene also prevented bone loss in a dose dependent manner. The results of five assays using raloxifene are combined in Table 3. Accordingly, each point reflects the responses of thirty rats and depicts a typical dose response curve for raloxifene in this model.
Results are reported as the mean + the standard error of the mean.
Table 2 Bone Density (mg/cm/cm) Ovariectomy control 170 + 3 (0.5 mL CMC oral) Intact control 220 + 4 (0.5 mL CMC oral) EE2 100 ~g/kg, oral 210 + 4 Table 3 Bone Density (mq/cm/cm) Ovariectomy control 171 + 3 (0.5 mL CMC oral) Intact control 222 + 3 (0.5 mL CMC oral) raloxifene 0.01 mg/kg, oral 176 + 3 raloxifene 0.10 mg/kg, oral 197 + 3 raloxifene 1.00 mg/kg, oral 201 + 3 raloxifene 10.00 mg/kg, oral 199 + 3 -Example 2 Other compounds of formula I were administered orally in the rat assay described in Example 1. Table 4 reports the effect of a 1 mg/kg dose of each compound in terms of a percent inhibition of bone loss.
Table 4 Compound % Inhibition Number of Bone LOssa a Percent inhibition of bone loss = (bone density of treated ovex animals - bone density of untreated ovex animals) + (bone density of estrogen treated ovex animals - bone density of untreated ovex animals) x 100.
This starting compound is protected, acylated at C-3 with a 4-(2-aminoethoxy)benzoyl group, and optionally deprotected to form the formula I compounds. Examples of the preparation of such compounds are provided in the U.S. Patents discussed above.
The compounds used in the methods of this invention form pharmaceutically-acceptable acid and, wherein Rl and/or R3 is hydrogen, base addition salts with a wide variety of organic and inorganic acids and bases, including the physiologically-acceptable salts which are often used in pharmaceutical chemistry. Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydriodic, nitric, sulfuric, phosphoric, hypophosphoric, and the like.
Salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used.
Such pharmaceutically-acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, and ~-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,6-dioate, caprate, caprylate, chloride, cinn~m~te~ cltrate, formate, fumarate, glycolate, heptanoate, decanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, terephthalate, phosphate, monohydro-genphosphate, dihydrogenphosphate, metaphosphate,pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzenesulfonate, p-bromophenylsulfonate, chlorobenzene-sulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methanesulfonate, naphthalene-l-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartrate, and the like. The most preferred salt is the hydrochloride salt.
The pharmaceutically-acceptable acid addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid. The reactants are generally combined in an organic solvent such as methanol, diethyl ether, or benzene. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration, or the solvent can be stripped off by conventional means.
Bases commonly used for formation of salts include ammonium hydroxide and alkali and alkaline earth metal hydroxides, carbonates, as well as aliphatic primary, secondary, and tertiary amines, and aliphatic diamines.
Bases especially useful in the preparation of addition salts include ammonium hydroxide, potassium carbonate, methylamine, diethylamine, ethylenediamine, and cyclohexylamine. These salts are generally prepared by reacting a formula I
compound, wherein Rl and/or R3 are hydrogen, with one of the above bases in an organic solvent, such as methanol, diethyl ether, or benzene. The salts are isolated as described in the preceding paragraph.
These pharmaceutically-acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.
The formula I compounds are preferably formulated prior to administration such as in a pharmaceutical formulation comprising a compound of formula I and a pharmaceutically-acceptable carrier, diluent, or excipient.
These pharmaceutical formulations are prepared by known procedures using well-known and readily available ingredients. In making these compositions, the active ingredient will usually be mixed with a carrier, diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, excipient,or medium for the active ingredient. The compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments containing, for example up to 10% by weight of active compound, soft and hard gelatin capsules, dermal patches, suppositories, sterile injectible solutions, and sterile packaged powders.
Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, micro-crystalline cellulose, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, cellulose or derivatives thereof, water syrup, methyl cellulose, methyl and propyl hydroxybenzoates, talc, magnesium sterate and mineral oil. The formulations can additionally include lubricating agents, wetting agents (e.g. surfactant), emulsifying and suspending agents, disintegrating agents, preserving agents, sweetening agents, or flavoring agents. Compositions of the inventions may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
The particular dosage of a compound of formula I
required to treat smoking-related bone loss or its symptoms, according to this invention, will depend upon the severity of the condition, the route of a & inistration, and related factors that will be decided by the attending physician.
Generally, effective daily doses will be from about 0.1 to about 1000 mg/day, and more typically from about 50 to about 200 mg/day. Such dosages will be a & inistered to a subject ~ 216~067 in need thereof from once to about three times each day, or more often as needed to effectively treat the condition or symptom.
It is usually preferred to administer a compound of formula I in the form of an acid addition salt, as is customary in the administration of pharmaceuticals bearing a basic group, such as the piperidino group. For such purposes the following oral dosage forms are available.
Formulations In the formulations which follow, ~Active ingredient" means a compound of formula I.
Formulation 1: Gelatin Capsules Hard gelatin capsules are prepared using the following:
Ingredient Quantity (mg/capsule) Active ingredient0.1 - 1000 Starch, NF O - 650 Starch flowable powder 0 - 650 Silicone fluid 350 centistokes 0 - 15 The ingredients are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules.
Examples of specific capsule formulations of raloxifene that have been made include those shown below:
Formulation 2: Raloxifene capsule Inqredient Quantity (mq/capsule) Raloxifene Starch, NF 112 Starch flowable powder 225.3 Silicone fluid 350 centistokes 1.7 i~ ~168067 Formulation 3: Raloxifene capsule Ingredient Quantity (mg/capsule) Raloxifene 5 Starch, NF 108 Starch flowable powder 225.3 Silicone fluid 350 centistokes 1.7 Formulation 4: Raloxifene capsule Ingredient Quantity (mq/capsule) Raloxifene 10 Starch, NF 103 Starch flowable powder 225.3 Silicone fluid 350 centistokes 1.7 Formulation 5: Raloxifene capsule Ingredient Quantity (mg/capsule) Raloxifene 50 Starch, NF 150 Starch flowable powder 397 Silicone fluid 350 centistokes 3.0 The specific formulations above may be changed in compliance with the reasonable variations provided.
A tablet formulation is prepared using the ingredients below:
Formulation 6: Tablets Ingredient Quantity (mg/tablet) Active ingredient 0.1 - 1000 Cellulose, microcrystalline0 - 650 Silicon dioxide, fumed 0 - 650 Stearate acid 0 - 15 The components are blended and compressed to form tablets.
Alternatively, tablets each containing 0.1 - 1000 mg of Active ingredient are made up as follows:
Formulation 7: Tablets Ingredient Quantity (mg/tablet) Active ingredient 0.1 - 1000 Starch 45 Cellulose, microcrystalline35 Polyvinylpyrrolidone 4 (as 10% solution in water) Sodium carboxymethyl cellulose 4.5 Magnesium stearate 0.5 Talc The Active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly.
The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50-60 C
and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 U.S. sieve, are then added 21630~ ~
to the granules which, after mixing, are compressed on a tablet machine to yield tablets.
Suspensions each containing 0.1 - 1000 mg of Active ingredient per 5 mL dose are made as follows:
Formul a t i on 8: Suspensi ons Ingredient Quantity (mg/5 ml) Active ingredient0.1 - 1000 mg Sodium carboxymethyl cellulose 50 mg Syrup 1.25 mg Benzoic acid solution 0.10 mL
Flavor q.v.
Color q.v.
Purified water to 5 mL
The Active ingredient is passed through a No. 45 mesh U.S.
sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.
- 216 ~ 0 6 i -Illustrative compounds that can be used in the methods of the present invention are shown in Table 1.
Table Compound No. Rl and R3 R2 Form 1 -C(O) ~ F piperidino base 2 -C(O) ~ F piperidino HCl 3 -C(O) ~ piperidino base 4 -C(O) ~ piperidino HCl -C(O)CH2CH2CH3 piperidino base 6 -C(O)CH2CH2CH3 piperidino HCl 7 -C(O)C(CH3)3 piperidino base 8 -C(O)C(CH3)3 piperidino HCl g -C(O)CH2C(CH3)3 piperidino base 10 -c(o)cH2c(cH3)3 piperidino HCl 11 -C(O) ~ CH3 piperidino HCl 12 -C(O) ~ piperidino base 13 H piperidino base 14 H piperidino HCl H pyrrolodino base 16 H pyrrolodino HCl 17 Hhexamethyleneimino HCl 18 CH3piperidino HCl The utility of the compounds of formula I is illustrated by the positive impact they have in at least one of the assays described below.
~ ` 2168067 Example A model of post-menopausal osteoporosis was used in which effects of different treatments upon femur density were determined. Seventy-five day old female Sprague Dawley rats (weight range of 225 g to 275 g) were obtained from Charles River Laboratories (Portage, MI). They were housed in groups of 3 and had ad libitum access to food (calcium content approximately 1%) and water. Room temperature was maintained at 22.2 + 1.7 C with a minimum relative humidity of 40%.
The photoperiod in the room was 12 hours light and 12 hours dark.
One week after arrival, the rats underwent bilateral ovariectomy under anesthesia [44 mg/kg Ketamine and 5 mg/kg Xylazine (Butler, Indianapolis, IN) administered intramuscularly]. Treatment with vehicle, estrogen, or a compound of formula I was initiated on the day of surgery following recovery from anesthesia. Oral dosage was by gavage in 0.5 mL of 1% carboxymethylcellulose (CMC). Body weight was determined at the time of surgery and weekly thereafter and the dosage was adjusted with changes in body weight. Vehicle or estrogen treated ovariectomized (ovex) rats and non-ovariectomized (intact) rats were evaluated in parallel with each experimental group to serve as negative and positive controls.
The rats were treated daily for 35 days (6 rats per treatment group) and sacrificed by decapitation on the 36th day. The 35 day time period was sufficient to allow maximal reduction in bone density, measured as described herein. The right femurs were excised and scanned at the distal metaphysis 1 mm from the patellar groove with single photon absorptiometry. Results of the densitometer measurements represent a calculation of bone density as a function of the bone mineral content and bone width.
The results of control treatments from five separate experiments are accumulated in Table 2. In summary, ovariectomy of the rats caused a reduction in femur density of about 25% as compared to intact vehicle treated controls.
Estrogen, administered in the orally active form of ethynyl estradiol (EE2), prevented this loss of bone in a dose dependent manner. Results are reported as the mean of measurements from thirty rats + the standard error of the mean.
In these studies, raloxifene also prevented bone loss in a dose dependent manner. The results of five assays using raloxifene are combined in Table 3. Accordingly, each point reflects the responses of thirty rats and depicts a typical dose response curve for raloxifene in this model.
Results are reported as the mean + the standard error of the mean.
Table 2 Bone Density (mg/cm/cm) Ovariectomy control 170 + 3 (0.5 mL CMC oral) Intact control 220 + 4 (0.5 mL CMC oral) EE2 100 ~g/kg, oral 210 + 4 Table 3 Bone Density (mq/cm/cm) Ovariectomy control 171 + 3 (0.5 mL CMC oral) Intact control 222 + 3 (0.5 mL CMC oral) raloxifene 0.01 mg/kg, oral 176 + 3 raloxifene 0.10 mg/kg, oral 197 + 3 raloxifene 1.00 mg/kg, oral 201 + 3 raloxifene 10.00 mg/kg, oral 199 + 3 -Example 2 Other compounds of formula I were administered orally in the rat assay described in Example 1. Table 4 reports the effect of a 1 mg/kg dose of each compound in terms of a percent inhibition of bone loss.
Table 4 Compound % Inhibition Number of Bone LOssa a Percent inhibition of bone loss = (bone density of treated ovex animals - bone density of untreated ovex animals) + (bone density of estrogen treated ovex animals - bone density of untreated ovex animals) x 100.
Claims (10)
1. A method for treating smoking-related bone loss which comprises administering to a human in need thereof a pharmaceutically-effective amount of a compound having the formula (I) wherein R1 and R3 are independently hydrogen, C1-C4 alkyl, -CO-(C1-C6 alkyl), or -CH2Ar, -CO-Ar, wherein Ar is phenyl or substituted phenyl;
R2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically-acceptable salt thereof.
R2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically-acceptable salt thereof.
2. The method of Claim 1 wherein R1 and R3 are independently hydrogen, C1-C4 alkyl, -CO-(C1-C6 alkyl), or benzyl; and R2 is piperidino or pyrrolidino.
3. The method of Claim 2 wherein R1 and R3 are independently hydrogen or C1-C4 alkyl, and R2 is piperidino or pyrrolidino.
4. The method of Claim 3 wherein R1 and R3 are hydrogen and R2 is piperidino or pyrrolidino.
5. The method of Claim 4 wherein R2 is piperidino.
6. The method of Claim 5 wherein said pharmaceutically-acceptable salt is the hydrochloride salt.
7. Use of a compound of the formula (I) wherein:
R1 and R3 are independently hydrogen, C1-C4 alkyl, -CO-(C1-C6 alkyl), -CH2Ar, COAr, wherein Ar is phenyl or substituted phenyl;
R2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino;
or a pharmaceutically-acceptable salt thereof;
for the manufacture of a medicament for treating smoking-related bone loss.
R1 and R3 are independently hydrogen, C1-C4 alkyl, -CO-(C1-C6 alkyl), -CH2Ar, COAr, wherein Ar is phenyl or substituted phenyl;
R2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino;
or a pharmaceutically-acceptable salt thereof;
for the manufacture of a medicament for treating smoking-related bone loss.
8. Use of a compound of the formula wherein:
R1 and R3 are independently hydrogen, and R2 is piperidino, or a pharmaceutically-acceptable salt thereof, for the manufacture of a medicament for treating smoking-related bone loss.
R1 and R3 are independently hydrogen, and R2 is piperidino, or a pharmaceutically-acceptable salt thereof, for the manufacture of a medicament for treating smoking-related bone loss.
9. A compound for use in treating smoking-related bone loss of the formula:
wherein:
R1 and R3 are independently hydrogen, C1-C4 alkyl, -CO-(C1-C6 alkyl), -CH2Ar, or -COAr, wherein Ar is R2 is selected from the group consisting of pyrrolidino, hexamethylenemino, or piperidino; or a pharmaceutically-acceptable salt thereof.
wherein:
R1 and R3 are independently hydrogen, C1-C4 alkyl, -CO-(C1-C6 alkyl), -CH2Ar, or -COAr, wherein Ar is R2 is selected from the group consisting of pyrrolidino, hexamethylenemino, or piperidino; or a pharmaceutically-acceptable salt thereof.
10. The compound as claimed in Claim 9, wherein R1 and R3 are hydrogen and R2 is piperidino, or a pharmaceutically-acceptable salt thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/381,036 US5571808A (en) | 1995-01-31 | 1995-01-31 | Method for treating smoking-related bone loss |
| US08/381,036 | 1995-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2168067A1 true CA2168067A1 (en) | 1996-08-01 |
Family
ID=23503398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002168067A Abandoned CA2168067A1 (en) | 1995-01-31 | 1996-01-25 | Method for treating smoking-related bone loss |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US5571808A (en) |
| EP (1) | EP0724881A1 (en) |
| JP (1) | JPH08231397A (en) |
| CA (1) | CA2168067A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
-
1995
- 1995-01-31 US US08/381,036 patent/US5571808A/en not_active Expired - Fee Related
-
1996
- 1996-01-25 EP EP96300534A patent/EP0724881A1/en not_active Withdrawn
- 1996-01-25 CA CA002168067A patent/CA2168067A1/en not_active Abandoned
- 1996-01-31 JP JP8015271A patent/JPH08231397A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08231397A (en) | 1996-09-10 |
| US5571808A (en) | 1996-11-05 |
| EP0724881A1 (en) | 1996-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU692811B2 (en) | Combination treatment for osteoporosis | |
| US5691355A (en) | Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs | |
| US5441966A (en) | Methods of inhibiting Turner's syndrome | |
| US5532254A (en) | Modulation of calcium channels using benzothiophenes | |
| EP0920863B1 (en) | The use of 2-Aryl-3-aroylbenzo(b)thiophenes for the treatment of estrogen deprivation syndrome | |
| US5571808A (en) | Method for treating smoking-related bone loss | |
| IL112044A (en) | Benzothiophene derivatives for use in inhibiting weight gain or inducing weight loss | |
| US5521214A (en) | Methods of inhibiting environmental estrogens | |
| CA2234404A1 (en) | Methods of inhibiting plasminogen activator inhibitor 1 | |
| EP0831822B1 (en) | The use of calcium channel antagonists for treating cardiac, renal and gastrointestinal disorders and hypertension | |
| CA2170480A1 (en) | Methods of inhibiting estrogen positive tumors of the brain or cns | |
| NZ286930A (en) | use of a benzothiophene derivative such as raloxifene and a progestin for treating osteoporosis | |
| MXPA97009467A (en) | Pharmaceutical compositions to minimize loss or | |
| CA2257535A1 (en) | A method for minimizing the uterotrophic effect of droloxifene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |